It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don’t specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach." title="" class="btn" data-container="body" data-html="true" data-id="253009" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="SRTD Biotech"> 135
Activities
Entity types
Location
Huthmacherstraße 20, 52428 Jülich, Germany
Jülich
Germany
Employees
Scale: 11-50
Estimated: 5
Engaged corporates
1Added in Motherbase
2 months agoseRNA – enter the next level of mRNA technology
It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don’t specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() HTGF | High-Tech Gründerfonds Venture Capital and Private Equity Principals | HTGF | High-Tech Gründerfonds Venture Capital and Private Equity Principals | Other 31 Jan 2025 | |